Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of stereotactic body radiation
therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary
peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less
damage to normal tissue.